Literature DB >> 21768534

Avastin hearing leads to more uncertainty over drug's future.

Merrill Goozner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768534     DOI: 10.1093/jnci/djr293

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

Review 1.  Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Authors:  Robert S Kerbel
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-09-26       Impact factor: 2.673

Review 2.  Tyrosine kinase inhibitors in breast cancer (Review).

Authors:  George Iancu; Dragos Serban; Cristinel Dumitru Badiu; Ciprian Tanasescu; Mihai Silviu Tudosie; Corneliu Tudor; Daniel Ovidiu Costea; Anca Zgura; Raluca Iancu; Danut Vasile
Journal:  Exp Ther Med       Date:  2021-12-03       Impact factor: 2.447

3.  Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.

Authors:  Stephen Dyar; Alvaro Moreno-Aspitia
Journal:  Breast Cancer (Auckl)       Date:  2011-11-28

4.  Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.

Authors:  Erez Hasnis; Dror Alishekevitz; Svetlana Gingis-Veltski; Rotem Bril; Ella Fremder; Tali Voloshin; Ziv Raviv; Amir Karban; Yuval Shaked
Journal:  Neoplasia       Date:  2014-06-20       Impact factor: 5.715

Review 5.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.